EPO rules in favor of Sanofi and Regeneron concerning Praluent

30 October 2020

The European Patent Office (EPO) Technical Boards of Appeal has ruled in French pharma major Sanofi (Euronext: SAN) and US partner Regeneron Pharmaceutical’s (Nasdaq: REGN) favor, invalidating certain claims of Amgen’s (Nasdaq: AMGN) European patent (EP 2 215 124) directed to PCSK9 (proprotein convertase subtilisin/kexin type 9) antibodies relevant to Praluent (alirocumab). Cholesterol-lowerer Praluent will continue to be available in European countries where it is approved for use and for sale.

“We are pleased with today’s decision by the European Patent Office, which upholds the rigorous standard for pharmaceutical patents that we argued for in this case, affirming that Amgen’s asserted claims against Sanofi in Europe are invalid,” said Karen Linehan, executive vice president, legal affairs and general counsel, Sanofi, adding: “This decision validates our years-long commitment to vigorously defending this case.”

Follows similar US court decision

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK